Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
EV-309
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
- NCT07566156 ↗
- Recruiting
- Astellas Pharma Global Development, Inc.
- Deep
We haven't built an HCP commentary report on EV-309 (enfortumab vedotin, pembrolizumab and 4 more in Urothelial Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on EV-309 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 14 | |
| YouTube | 5 | |
| Podcasts | 5 |
The trial
ClinicalTrials.gov- Official title
- A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE ENFORTUMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PARTICIPANTS WITH MUSCLE-INVASIVE BLADDER CANCER WHO ARE INELIGIBLE FOR OR HAVE ELECTED NOT TO UNDERGO CYSTECTOMY
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Urothelial Cancer; Urinary Bladder Neoplasms
- Interventions
- Enfortumab vedotin; Conventional Radiotherapy; Hypofractionated Radiotherapy; Cisplatin; Fluorouracil; Mitomycin C; Gemcitabine; Pembrolizumab
- Arms
- Arm A · Experimental
- Arm B · Active comparator
- Enrollment
- 390 (estimated)
- Primary outcomes
- Bladder-intact Event Free Survival (BI-EFS) by Blinded Independent Central Review (BICR)
- Overall Survival (OS)
- Sponsor
- Astellas Pharma Global Development, Inc. with Pfizer
- Start
- May 11, 2026
- Primary completion
- Mar 31, 2030 (estimated)
- Results posted
- No
- Registry record
- NCT07566156 · updated Oct 28, 2026